MedKoo Biosciences/TAS108 citrate/202840/25mg

RelatedCAS#:229634-98-4(citrate) 229634-97-3(freebase) 

Synonym:TAS108,TAS-108,TAS108,SR16234,SR16234,SR-16234

IUPAC/ChemicalName:(7R,8S,9S,13R,14S,17R)-17-(2-(4-((diethylamino)methyl)-2-methoxyphenoxy)ethyl)-7,13-dimethyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol2-hydroxypropane-1,2,3-tricarboxylate

InChiKey:VOHOCSJONOJOSD-SCIDSJFVSA-N

InChiCode:InChI=1S/C33H47NO3.C6H8O7/c1-6-34(7-2)21-23-8-13-30(31(19-23)36-5)37-17-15-25-9-12-29-32-22(3)18-24-20-26(35)10-11-27(24)28(32)14-16-33(25,29)4;7-3(8)1-6(13,5(11)12)2-4(9)10/h8,10-11,13,19-20,22,25,28-29,32,35H,6-7,9,12,14-18,21H2,1-5H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t22-,25-,28-,29+,32-,33-;/m1./s1

SMILESCode:OC1=CC=C2[C@@]3([H])CC[C@]4(C)[C@@H](CCOC5=CC=C(C=C5OC)CN(CC)CC)CC[C@@]4([H])[C@]3([H])[C@H](C)CC2=C1.O=C(CC(C(O)=O)(O)CC(O)=O)O

TechnicalData

References

1:InajiH,IwataH,NakayamaT,YamamotoN,SatoY,TokudaY,AogiK,SajiS,WatanabeK,SaitoT,YoshidaM,SatoN,SaekiT,TakatsukaY,KuranamiM,YamashitaH,KikuchiA,TabeiT,IkedaT,NoguchiS.RandomizedphaseIIstudyofthreedosesoforalTAS-108inpostmenopausalpatientswithmetastaticbreastcancer.CancerSci.2012Sep;103(9):1708-13.doi:10.1111/j.1349-7006.2012.02354.x.Epub2012Jul16.PubMedPMID:22676245.

2:BuzdarA,VogelC,SchwartzbergL,GarinA,PerezA,IngleJ,HoughtonM,ZergebelC,KimballB.Randomizeddouble-blindphase2trialof3dosesofTAS-108inpatientswithadvancedormetastaticpostmenopausalbreastcancer.Cancer.2012Jul1;118(13):3244-53.doi:10.1002/cncr.26419.Epub2011Nov1.PubMedPMID:22045595.

3:KumagaiY,FujitaT,OzakiM,YokotaS,MaedaM,ShidaM,OtaniY,YamayaH,TsurutaH.Safety,tolerABIlityandpharmacokineticsofTAS-108,anovelanti-oestrogen,inhealthypost-menopausalJapanesewomen:aphaseIsingleoraldosestudy.BasicClinPharmacolToxicol.2009May;104(5):352-9.doi:10.1111/j.1742-7843.2008.00373.x.PubMedPMID:19175362.

4:SaekiT,NoguchiS,AogiK,InajiH,TabeiT,IkedaT.EvaluationofthesafetyandtolerabilityoforalTAS-108inpostmenopausalpatientswithmetastaticbreastcancer.AnnOncol.2009May;20(5):868-73.doi:10.1093/annonc/mdn714.Epub2009Jan15.PubMedPMID:19150935.

5:YamayaH,SaekiM,YoshidaK,ShibataJ,YanoS,SatoY,TakaoA,ShindoT,BuzdarAU,NagayamaS.Distributionof(7alpha)-21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3-propanetricarboxylate([14C]TAS-108)anditsmetabolitesaftersingleoraladministrationtoratsbearing7,12-dimethylbenz(alpha)anthracene-inducedmammarytumor.DrugMetabDispos.2006Feb;34(2):331-8.Epub2005Nov18.PubMedPMID:16299166.

6:YamayaH,YoshidaK,KuritaniJ,YonezawaJ,TsudaM,ShindoT,NagayamaS,BuzdarAU.Safety,tolerability,andpharmacokineticsofTAS-108innormalhealthypost-menopausalfemalesubjects:aphaseIstudyonsingleoraldose.JClinPharmTher.2005Oct;30(5):459-70.Erratumin:JClinPharmTher.2006Apr;31(2):204.Yonezawa,JI[correctedtoYonezawa,J].PubMedPMID:16164493.

7:BuzdarAU.TAS-108:anovelsteroidalantiestrogen.ClinCancerRes.2005Jan15;11(2Pt2):906s-8s.Review.PubMedPMID:15701885.

8:YamamotoY,ShibataJ,YonekuraK,SatoK,HashimotoA,AoyagiY,WierzbaK,YanoS,AsaoT,BuzdarAU,TeradaT.TAS-108,anoveloralsteroidalantiestrogenicagent,isapureantagonistonestrogenreceptoralphaandapartialagonistonestrogenreceptorbetawithlowuterotrophiceffect.ClinCancerRes.2005Jan1;11(1):315-22.PubMedPMID:15671561.

9:BlakelyLJ,BuzdarA,ChangHY,FryeD,TheriaultR,ValeroV,RiveraE,BooserD,KuritaniJ,TsudaM.AphaseIandpharmacokineticstudyofTAS-108inpostmenopausalfemalepatientswithlocallyadvanced,locallyrecurrentinoperable,orprogressivemetastaticbreastcancer.ClinCancerRes.2004Aug15;10(16):5425-31.PubMedPMID:15328180.